Literature DB >> 14504921

Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.

Fiona Errington1, Elaine Willmore, Chrysoula Leontiou, Michael J Tilby, Caroline A Austin.   

Abstract

PURPOSE: DNA topoisomerase II (topo II) is an important cellular target for chemotherapeutic agents. Human cells have two isoforms of topo II (alpha and beta), and both are inhibited by the chemotherapeutic agents etoposide, amsacrine (mAMSA) and mitoxantrone. It is known that the cytotoxic importance of topo IIalpha or topo IIbeta drug-induced complexes differs depending on which drug is present. This study was designed to (a) assess isoform-specific formation and reversal of topo IIalpha and beta cleavable complexes, and (b) determine whether the cytotoxic importance of either isoform was related to differences in the longevity of the complexes.
METHODS: Mouse embryonic fibroblasts (MEFs) were used to study the cellular response to the topo II poisons etoposide, mitoxantrone and mAMSA. The longevity of topo IIalpha and beta complexes was determined using the TARDIS assay. This immunofluorescence assay can differentiate between the topo II isoforms and thus allowed us to investigate the persistence and importance of topo IIalpha and beta complexes for the first time.
RESULTS: In MEFs treated with etoposide, 50% of topo IIalpha complexes dissociated within 40 min whereas dissociation of topo IIbeta complexes took only 20 min. Disappearance of complexes was a slower process for mitoxantrone-treated cells. The time taken to reduce topo IIalpha and topo IIbeta cleavable complexes by 50% was 10 and 6 h, respectively. In contrast, mAMSA-stabilized topo IIalpha and topo IIbeta cleavable complexes were equally stable (dissociation within 15 min for both isoforms). These stability data were confirmed using an in vitro assay.
CONCLUSIONS: We previously demonstrated that topo IIalpha is the major target for etoposide and mitoxantrone but that both topo IIalpha and topo IIbeta are important for mAMSA cytotoxicity. The longevity of the topo IIalpha and beta cleavable complexes shown here is therefore an important factor in determining the cytotoxic sensitivity of either isoform to these drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504921     DOI: 10.1007/s00280-003-0701-1

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Effect of ciprofloxacin-induced prostaglandin E2 on interleukin-18-treated monocytes.

Authors:  Hideo Kohka Takahashi; Hiromi Iwagaki; Dong Xue; Goutarou Katsuno; Sachi Sugita; Kenji Mizuno; Shuji Mori; Shinya Saito; Tadashi Yoshino; Noriaki Tanaka; Masahiro Nishibori
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Evaluating the genotoxicity of topoisomerase-targeted antibiotics.

Authors:  Daniel J Smart; Anthony M Lynch
Journal:  Mutagenesis       Date:  2011-12-07       Impact factor: 3.000

3.  Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.

Authors:  Mandeep Atwal; Rebecca L Swan; Chloe Rowe; Ka C Lee; David C Lee; Lyle Armstrong; Ian G Cowell; Caroline A Austin
Journal:  Mol Pharmacol       Date:  2019-08-09       Impact factor: 4.436

4.  Topoisomerase IIalpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure.

Authors:  Sébastien Soubeyrand; Louise Pope; Robert J G Haché
Journal:  Mol Oncol       Date:  2009-10-09       Impact factor: 6.603

5.  Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.

Authors:  Brian B Hasinoff; Xing Wu; Daywin Patel; Ragu Kanagasabai; Soumendrakrishna Karmahapatra; Jack C Yalowich
Journal:  J Pharmacol Exp Ther       Date:  2015-12-11       Impact factor: 4.030

6.  Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatin.

Authors:  Ian G Cowell; Nikolaos Papageorgiou; Kay Padget; Gary P Watters; Caroline A Austin
Journal:  Nucleus       Date:  2011 Jan-Feb       Impact factor: 4.197

7.  Role of Topoisomerase IIβ in DNA Damage Response following IR and Etoposide.

Authors:  Nicola J Sunter; Ian G Cowell; Elaine Willmore; Gary P Watters; Caroline A Austin
Journal:  J Nucleic Acids       Date:  2010-08-19

8.  Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.

Authors:  Catriona Parker; Rachel Waters; Carly Leighton; Jeremy Hancock; Rosemary Sutton; Anthony V Moorman; Philip Ancliff; Mary Morgan; Ashish Masurekar; Nicholas Goulden; Nina Green; Tamas Révész; Philip Darbyshire; Sharon Love; Vaskar Saha
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

9.  MRE11 facilitates the removal of human topoisomerase II complexes from genomic DNA.

Authors:  Ka Cheong Lee; Kay Padget; Hannah Curtis; Ian G Cowell; Davide Moiani; Zbyslaw Sondka; Nicholas J Morris; Graham H Jackson; Simon J Cockell; John A Tainer; Caroline A Austin
Journal:  Biol Open       Date:  2012-07-11       Impact factor: 2.422

10.  Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.

Authors:  Ka C Lee; Rebecca L Bramley; Ian G Cowell; Graham H Jackson; Caroline A Austin
Journal:  Biochem Pharmacol       Date:  2016-01-12       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.